Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor-1 (PD-1). We have now expanded this study to evaluate the efficacy of PD-1 blockade in patients with advanced mismatch repair-deficient cancers across 12 different tumor types. Objective radiographic responses were observed in 53% of patients, and complete responses were achieved in 21% of patients. Responses were durable, with median progression-free survival and overall survival still not reached. Functional…

• CF
  Commonwealth Fund

  Award: award315544
• LF
  Lustgarten Foundation

  Award: award315545
• LI
  Ludwig Institute for Cancer Research

  Award: award315547
• SA
  Swim Across America

  Award: award315543
• SU
  Stand Up To Cancer

  Award: award315548
• BI
  Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

  Award: award315542